Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The drug, which is named MariTide and delivered in a monthly injection, is some time away from being sold. The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year.
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.
Amgen share price plummets despite Phase II weight loss success
Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had hoped for more.
New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
The Wall Street Journal on MSN5h
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Health on MSN22h
Biden Says Medicare, Medicaid Should Cover Obesity Drugs—What Could That Mean for Access?
The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...
Biden administration proposes expanding obesity drug coverage under Medicare and Medicaid
The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Biden proposes anti-obesity drug rule
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden proposes Medicaid, Medicare cover ...
Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
McKnight's Long-Term Care News3d
CMS’ obesity drug coverage implications for nursing home patients
A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity ...
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...